{"entity":{"id":"nct06747845","kind":"trial","name":"Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy","aka":["ParpVax2"],"tldr":"A phase 2 trial of niraparib and ipilimumab in pancreatic cancer, run by Abramson Cancer Center at Penn Medicine, now recruiting.","summary":"Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy is a phase 2, randomised interventional study registered as NCT06747845 by Abramson Cancer Center at Penn Medicine, with a registry enrolment figure of 68 participants, started 2025-05-07 and due to reach its primary completion in 2028-06. Interventions recorded: Niraparib; FOLFIRI; Ipilimumab. Conditions listed: Pancreatic Adenocarcinoma Metastatic. Primary outcome: Progression-free survival (PFS) in the experimental arm. Pancreatic eligibility wording from the registry: \"* Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma with metastatic disease\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06747845","url":"https://clinicaltrials.gov/study/NCT06747845"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor","parp-inhibitor"],"targets":[],"drugs":["niraparib","ipilimumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06747845","phase":"2","setting":"ParpVax2: A Phase II Study Of Maintenance Niraparib Plus Ipilimumab In Patients With Metastatic Pancreatic Cancer Whose Disease Has Not Progressed On Platinum-Based Therapy","sponsor":"Abramson Cancer Center at Penn Medicine","enrolled":68,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06747845/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}